Abstract
Heart failure is a complex syndrome whose phenotypic presentation and disease progression depends on a complex network of adaptive and maladaptive responses. One of these responses is the endothelial release of NRG (neuregulin)-1-a paracrine growth factor activating ErbB2 (erythroblastic leukemia viral oncogene homolog B2), ErbB3, and ErbB4 receptor tyrosine kinases on various targets cells. NRG-1 features a multitasking profile tuning regenerative, inflammatory, fibrotic, and metabolic processes. Here, we review the activities of NRG-1 on different cell types and organs and their implication for heart failure progression and its comorbidities. Although, in general, effects of NRG-1 in heart failure are compensatory and beneficial, translation into therapies remains unaccomplished both because of the complexity of the underlying pathways and because of the challenges in the development of therapeutics (proteins, peptides, small molecules, and RNA-based therapies) for tyrosine kinase receptors. Here, we give an overview of the complexity to be faced and how it may be tackled.
| Original language | English |
|---|---|
| Article number | e006288 |
| Journal | Circulation: Heart Failure |
| Volume | 12 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 2019 |
| Externally published | Yes |
Keywords
- Animals
- Cardiovascular Agents/therapeutic use
- Chronic Disease
- Endothelial Cells/drug effects
- ErbB Receptors/metabolism
- Heart Failure/drug therapy
- Humans
- Ligands
- Molecular Targeted Therapy
- Neuregulin-1/metabolism
- Signal Transduction
Fingerprint
Dive into the research topics of 'Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor During Chronic Heart Failure'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver